Effect of postprandial blood glucose level by the continuity intake of salmon milt peptides in placebo-controlled double blind cross over clinical trial

Effect of postprandial blood glucose level by the continuity intake of salmon milt peptides in placebo-controlled double blind cross over clinical trial - Effect of salmon milt peptides on postprandial blood glucose level

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016509

Enrollment

Registered

2015-02-11

Start date

2015-02-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postprandial hyperglycemia

Interventions

Intake 500 mg salmon milt peptides capsule for 1 week, and take wash out period for 1 week, and then, intake placebo capsule for 1 week. Intake placebo capsule for 1 week, and take wash out period for

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Subjects with high serum glucose levels at 60 min after oral glucose load. (2)Subjects who agree to participate in the current study with written informed consent.

Exclusion criteria

Exclusion criteria: (1) Subjects who are under medication for diabetes and dyslipidemia. (2) HbA1c>=6.6% (3) FPG>=126mg/dl (4) Subjects with insulin resistance (HOMA-IR>=2.5) (5) Subjects with serious disease and infection (6) Subjects with clinical history of gastrointestinal surgery. (7) Subjects with unusually high and/or low blood pressure, or with abnormal hematological data. (8) Subjects with serious anemia. (9) Subjects with frequent complaints of post-menopausal symptoms. (10)Subjects with a history of allergy to medicine and food, especially salmon and gelatin. (11) Subjects routinely on supplementation which would affect glucose metabolism. (12) Subjects routinely on supplementation which would affect lipid metabolism. (13) Heavy smokers and alcohol addicts, or subjects with irregular lifestyle. (14) Subjects who donate 400ml whole blood within 12 weeks or who donate plasma or platelets within 4 weeks prior to supplementation. (15) Subjects who are pregnant or under lactation, or ones who would be expected to be pregnant during the study. (16) Subjects who participate in other clinical trials within the last one month prior to the current clinical trial. (17) Subjects who are not eligible due to physician's judgment.

Design outcomes

Primary

Measure	Time frame
Serum glucose level	—

Secondary

Measure	Time frame
Insulin	—

Countries

Japan

Contacts

Public ContactDir. Prof. Jun Nishihira, M.D.

Hokkaido Information University Health Information Science Center

nishihira@do-johodai.ac.jp011-385-4430

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026